Long-term immunogenicity of hepatitis B vaccination and policy for booster:: an Italian multicentre study

被引:276
作者
Zanetti, AR
Mariano, A
Romanò, L
D'Amelio, R
Chironna, M
Coppola, RC
Cuccia, M
Mangione, R
Marrone, F
Negrone, FS
Parlato, A
Zamparo, E
Zotti, C
Stroffolini, T
Mele, A
机构
[1] Univ Milan, Inst Virol, I-20133 Milan, Italy
[2] Ist Super Sanita, Ctr Nazl Epidemiol Sorveglianza & Promoz Salute, I-00161 Rome, Italy
[3] Minit Difesa, Direz Gen Sanita Mil, Rome, Italy
[4] Univ Roma La Sapienza, Fac Med & Chirurg 2, Rome, Italy
[5] Univ Bari, Dipartimento Med Interna & Med Pubbl, Sez Igiene, Bari, Italy
[6] Univ Cagliari, Dipartimento Sanita Pubbl, Cagliari, Italy
[7] AUSL3 Catania, Dipartimento Prevenz, Serv Epidemiol & Prevenz, Catania, Italy
[8] AUSL1 Agrigento, Serv Sanita Pubbl Epidemiol Med Prevent, Unita Operat Licata, Licata, Italy
[9] ASL Cesena, Cesena, Italy
[10] ASL2 Potenza, Unita Operat Igiene & Sanita Pubbl, Potenza, Italy
[11] ASL NA2, Dipartimento Epidemiol & Prevenz, Naples, Italy
[12] ASS6 Friuli Occidentale, Dipartimento Prevenz, Pordenone, Italy
[13] Univ Turin, Dipartimento Sanita Pubbl & Microbiol, Turin, Italy
[14] Osped S Giacomo, Dipartimento Gastroenterol, Rome, Italy
关键词
D O I
10.1016/S0140-6736(05)67568-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Universal anti-hepatitis-B vaccination of infants and adolescents was implemented in Italy in 1991. We undertook a multicentre study in previously vaccinated individuals to assess the duration of immunity and need for booster, over 10 years after vaccination. Methods In 1212 children and 446 Italian Air Force recruits vaccinated as infants and adolescents, respectively, we measured the concentrations of antibodies to hepatitis-B surface antigen (anti-HBs) and the presence of antibodies to hepatitis-B core antigen (anti-HBc) at enrolment; postimmunisation values were not available. Individuals positive for anti-HBc were tested for hepatitis B surface antigen (HBsAg) and hepatitis B viral DNA. Individuals with anti-HBs concentrations at 10 IU/L or more were regarded as protected; those with antibody less than 10 IU/L were given a booster dose and retested 2 weeks later. Individuals showing postbooster anti-HBs concentrations of less than 10 IU/L were offered two additional vaccine doses and retested 1 month after the third dose. Findings Protective anti-HBs concentrations were retained in 779 (64%, 95% CI 61.6-67) children and 398 (89%, 86.4-92.1) recruits. We recorded antibody amounts of less than 10 IU/L in 433 children (36%, 33-38.4) and 48 (11%, 7.9-13.6) recruits. One child and four recruits were positive for anti-HBc, but negative for HBsAg and hepatitis B viral DNA. Antibody concentrations were higher in recruits than in children (geometric mean titre 234.8 IU/L vs 32.1 IU/L, p=0.0001). 332 (97%) of 342 children and 46 (96%) of 48 recruits who received a booster showed an anamnestic response, whereas ten (3%) children and two (4%) recruits remained negative for anti-HBs or had antibody concentrations of less than 10 IU/L. Prebooster and postbooster antibody titres were strongly correlated with each other in both groups. All individuals given two additional vaccine doses (eight children and two recruits) showed anti-HBs amounts of more than 10 IU/L at 1 month after vaccination. Interpretation Strong immunological memory persists more than 10 years after immunisation of infants and adolescents with a primary course of vaccination. Booster doses of vaccine do not seem necessary to ensure long-term protection.
引用
收藏
页码:1379 / 1384
页数:6
相关论文
共 30 条
[1]  
*ACIP, 1982, MMWR-MORBID MORTAL W, V31, P317
[2]  
Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6
[3]   Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low [J].
Boxall, EH ;
Sira, JA ;
El-Shuhkri, N ;
Kelly, DA .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (07) :1264-1269
[4]   Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization [J].
Chang, MH .
LIVER INTERNATIONAL, 2003, 23 (05) :309-314
[5]   Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children [J].
Chang, MH ;
Chen, CJ ;
Lai, MS ;
Hsu, HM ;
Wu, TC ;
Kong, MS ;
Liang, DC ;
Shau, WY ;
Chen, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (26) :1855-1859
[6]   Long-term protection of hepatitis B vaccine: Lessons from Alaskan experience after 15 years [J].
Chen, DS .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (05) :384-385
[7]   Persistence of anti-HBs 5 years after the introduction of routine infant and adolescent vaccination in Italy [J].
Faustini, A ;
Franco, E ;
Sangalli, M ;
Spadea, T ;
Calabrese, RM ;
Cauletti, M ;
Perucci, CA .
VACCINE, 2001, 19 (20-22) :2812-2818
[8]   Prevention of viral hepatitis in Italy [J].
FitzSimons, D ;
François, G ;
Bonanni, P ;
Mele, A ;
Zanetti, A ;
Stroffolini, T ;
Crovari, P ;
Van DaMme, P .
VACCINE, 2004, 22 (29-30) :4092-4096
[9]   Chronic hepatitis D: A vanishing disease? An Italian multicenter study [J].
Gaeta, GB ;
Stroffolini, T ;
Chiaramonte, M ;
Ascione, T ;
Stornaiuolo, G ;
Lobello, S ;
Sagnelli, E ;
Brunetto, MR ;
Rizzetto, M .
HEPATOLOGY, 2000, 32 (04) :824-827
[10]   Elimination of new chronic hepatitis B virus infections: Results of the Alaska immunization program [J].
Harpaz, R ;
McMahon, BJ ;
Margolis, HS ;
Shapiro, CN ;
Havron, D ;
Carpenter, G ;
Bulkow, LR ;
Wainwright, RB .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (02) :413-418